Trial Profile
A randomized, double-blind, placebo-controlled, single-dose phase I clinical study evaluated the safety, tolerability, and pharmacokinetic characteristics of RMX1002 in healthy Chinese adult subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2021
Price :
$35
*
At a glance
- Drugs Grapiprant (Primary)
- Indications Arthritis; Familial adenomatous polyposis; Pain
- Focus Pharmacokinetics; Proof of concept
- 13 Mar 2018 New trial record